U.S. markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
110.52-1.11 (-0.99%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Performance Outlook
Previous Close111.63
Open111.20
Bid110.20 x 1400
Ask110.40 x 1100
Day's Range109.48 - 111.56
52 Week Range62.55 - 113.41
Volume9,096,982
Avg. Volume8,314,030
Market Cap195.049B
Beta (5Y Monthly)0.82
PE Ratio (TTM)24.17
EPS (TTM)4.57
Earnings DateFeb 03, 2021
Forward Dividend & Yield5.20 (4.71%)
Ex-Dividend DateJan 14, 2021
1y Target Est117.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-15% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
    PR Newswire

    Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference

    Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in patients with spasticity and efficacy and tolerability in patients with cervical dystonia, respectively. Also to be presented are data on incontinence product use and associated costs in patients with overactive bladder treated with onabotulinumtoxinA. Additionally, results from a randomized controlled clinical trial on the efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children and findings from a study on the safety, pharmacodynamic response and treatment satisfaction, with increasing doses of onabotulinumtoxinA in patients with moderate to severe dynamic glabellar lines will be presented. These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17.

  • TheStreet.com

    Best Healthcare Stocks to Buy for 2021

    Real Money contributor Stephen Guilfoyle checks which sector names could perform best over the coming year.

  • AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
    Zacks

    AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

    AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day.